Maitz Kathrin, Valadez-Cosmes Paulina, Raftopoulou Sofia, Kindler Oliver, Kienzl Melanie, Bolouri Hamid, Houghton A McGarry, Schicho Rudolf, Heinemann Akos, Kargl Julia
Division of Pharmacology, Otto Loewi Research Center, Medical University of Graz, 8010 Graz, Austria.
Center for Systems Immunology, Benaroya Research Center, Seattle, WA 98101, USA.
Cancers (Basel). 2023 Dec 8;15(24):5767. doi: 10.3390/cancers15245767.
Lung cancer is the leading cause of cancer-related death worldwide. Discoidin domain receptor 1 (DDR1), a tyrosine kinase receptor, has been associated with poor prognosis in patients with non-small cell lung cancer (NSCLC). However, its role in tumorigenesis remains poorly understood. This work aimed to explore the impact of DDR1 expression on immune cell infiltration in lung adenocarcinoma. Pharmacological inhibition and knockout of DDR1 were used in an immunocompetent mouse model of KRAS/p53-driven lung adenocarcinoma (LUAD). Tumor cells were engrafted subcutaneously, after which tumors were harvested for investigation of immune cell composition via flow cytometry. The Cancer Genome Atlas (TCGA) cohort was used to perform gene expression analysis of 509 patients with LUAD. Pharmacological inhibition and knockout of DDR1 increased the tumor burden, with DDR1 knockout tumors showing a decrease in CD8 cytotoxic T cells and an increase in CD4 helper T cells and regulatory T cells. TCGA analysis revealed that low-DDR1-expressing tumors showed higher FoxP3 (regulatory T-cell marker) expression than high-DDR1-expressing tumors. Our study showed that under certain conditions, the inhibition of DDR1, a potential therapeutic target in cancer treatment, might have negative effects, such as inducing a pro-tumorigenic tumor microenvironment. As such, further investigations are necessary.
肺癌是全球癌症相关死亡的主要原因。盘状结构域受体1(DDR1)是一种酪氨酸激酶受体,与非小细胞肺癌(NSCLC)患者的不良预后相关。然而,其在肿瘤发生中的作用仍知之甚少。这项研究旨在探讨DDR1表达对肺腺癌免疫细胞浸润的影响。在KRAS/p53驱动的肺腺癌(LUAD)免疫健全小鼠模型中,采用药物抑制和基因敲除DDR1的方法。将肿瘤细胞皮下接种,之后收获肿瘤,通过流式细胞术研究免疫细胞组成。利用癌症基因组图谱(TCGA)队列对509例LUAD患者进行基因表达分析。DDR1的药物抑制和基因敲除增加了肿瘤负荷,DDR1基因敲除的肿瘤中CD8细胞毒性T细胞减少,CD4辅助性T细胞和调节性T细胞增加。TCGA分析显示,低DDR1表达的肿瘤比高DDR1表达的肿瘤显示出更高的FoxP3(调节性T细胞标志物)表达。我们的研究表明,在某些情况下,抑制DDR1(癌症治疗中的一个潜在治疗靶点)可能会产生负面影响,如诱导促肿瘤的肿瘤微环境。因此,有必要进一步研究。